Syndax Pharmaceuticals Stock In The News
| SNDX Stock | USD 15.85 0.25 1.60% |
Our overall analysis of Syndax Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Syndax Pharmaceuticals. The specific impact of Syndax Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Syndax Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Syndax Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Syndax Pharmaceuticals Backtesting and Syndax Pharmaceuticals Hype Analysis. For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.
Syndax |
Syndax Pharmaceuticals Today Top News and Investor Outlook
Syndax Pharmaceuticals Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Syndax and other traded companies coverage with news coverage. We help investors stay connected with Syndax headlines for the 22nd of November to make an informed investment decision based on correlating the impacts of news items on Syndax Stock performance. Please note that trading solely based on the Syndax Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Syndax Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Syndax earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Syndax Pharmaceuticals that are available to investors today. That information is available publicly through Syndax media outlets and privately through word of mouth or via Syndax internal channels. However, regardless of the origin, that massive amount of Syndax data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Syndax Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Syndax Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Syndax Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Syndax Pharmaceuticals alpha.
Syndax Largest EPS Surprises
Earnings surprises can significantly impact Syndax Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-03-08 | 2020-12-31 | -0.49 | -0.44 | 0.05 | 10 | ||
2019-11-07 | 2019-09-30 | -0.47 | -0.41 | 0.06 | 12 | ||
2016-08-09 | 2016-06-30 | -0.53 | -0.47 | 0.06 | 11 | ||
2018-11-05 | 2018-09-30 | -0.76 | -0.68 | 0.08 | 10 | ||
2016-11-10 | 2016-09-30 | -0.76 | -0.84 | -0.08 | 10 | ||
2023-08-03 | 2023-06-30 | -0.73 | -0.64 | 0.09 | 12 |
Syndax Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Syndax Pharmaceuticals Stock. Current markets are slightly bullish. About 58% of major world exchanges and indexes are currently up. See today's market update for more information.
21st of November 2024
Kura Oncology Gets 330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin at medcitynews.com
19th of November 2024
Incyte sinks on setback for drugs acquired in 750M buyout at finance.yahoo.com
18th of November 2024
Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval at medcitynews.com
14th of November 2024
Kynam Capital Management, LP Reduces Stake in Cogent Biosciences Inc at gurufocus.com
13th of November 2024
Syndax Pharmaceuticals SWOT analysis biotech stock poised for growth amid FDA approvals at investing.com
12th of November 2024
Syndax Pharmaceuticals Shares Gap Down Time to Sell at thelincolnianonline.com
7th of November 2024
Royalty Pharma PLC Q3 2024 Earnings Call Highlights Strong Growth and Strategic Acquisitio... at finance.yahoo.com
6th of November 2024
Syndax Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strategic Advances and ... at finance.yahoo.com
5th of November 2024
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting at finance.yahoo.com
22nd of October 2024
Incyte Gears Up to Report Q3 Earnings Heres What You Should Know at finance.yahoo.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Syndax Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Syndax Pharmaceuticals' short interest history, or implied volatility extrapolated from Syndax Pharmaceuticals options trading.
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.